Multimel N4-550 E

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin, the active ingredients in Multimel N4-550 E, are an amino acid supplement presented as an intravenous solution for IV use. It provides essential amino acids for protein synthesis and supports nitrogen balance in patients requiring parenteral nutrition.

GNH USA supplies Multimel N4-550 E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Multimel N4-550 E is used in the context of parenteral nutrition to address protein and nitrogen needs in patients who cannot receive enteral feeding. - Inability to tolerate enteral feeding: supplies a complete amino acid profile via intravenous route to meet protein and nitrogen requirements. - Post‑operative or trauma patients: supports wound healing and muscle protein synthesis during catabolic stress. - Critically ill patients: helps maintain nitrogen balance and prevents essential amino acid deficiency.

Adverse reactions may occur with any intravenous amino acid solution.

Common Side Effects: - Phlebitis or infusion site irritation. - Mild hyperglycemia. - Electrolyte disturbances (e.g., mild hyperkalemia). - Nausea or vomiting.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Severe hyperosmolarity leading to renal dysfunction. - Metabolic acidosis or alkalosis. - Hepatic encephalopathy in patients with severe liver disease.

When using Multimel N4-550 E, clinicians should observe several safety measures. - Renal function: assess baseline creatinine and adjust infusion rate as needed. - Electrolytes: monitor serum potassium, sodium, and calcium regularly. - Blood glucose: check glucose levels, especially in diabetic patients. - Hepatic impairment: use with caution in severe liver disease. - Hypersensitivity: discontinue if signs of an allergic reaction appear. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid): - High‑dose potassium chloride: risk of severe hyperkalemia. - Concurrent nitrogenous waste products (e.g., urea supplements): may exacerbate hyperammonemia.

Moderate Interactions (Monitor Closely): - Insulin or other hypoglycemic agents: increased risk of hypoglycemia. - Loop diuretics: may cause electrolyte shifts requiring closer monitoring. - Other parenteral nutrition components (calcium, phosphate): risk of precipitation if mixed improperly.